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Several immunostimulatory monoclonal antibodies
(ISmAbs) that derepress and unleash antitumor immune
responses are showing efficacy in cancer clinical trials.
MAbs anti-B7-H1 (PD-L1) block a critical inhibitory
pathway for T cells, while antibodies anti-CD137 and
OX40 provide intense T cell costimulation. Document-
ing efficacy of immunotherapies on spontaneous tumors
arising in oncogene transgenic mice is considered more
predictive than experiments on transplanted tumors.
A combination of these ISmAbs has been tested on a
transgenic mouse model of spontaneous primary liver can-
cer in which c-myc drives transformation and the tumor
cells express ovalbumin as a surrogate transgenic antigen.
The induced tumor lymphocyte infiltrates and immune
mechanisms of action were studied. The triple combina-
tion of mAbs clearly extended survival of mice bearing
hepatocellular carcinomas (HCC) and synergized with
adoptive T cell therapy with activated TCR-transgenic
T cells that recognize OVA. Mice undergoing therapy
showed a clear increase in the tumor tissue infiltration by
activated and blastic CD8 T lymphocytes expressing the
ISmAb-targeted receptors. The triple combination of
ISmAbs did not result in enhanced OVA-specific CTL
activity but other antigens in cell lines derived from such
HCC were recognized by the elicited tumor infiltrating
T lymphocytes. Indeed adoptive transfer of OT-1 cells to
tumor bearing mice resulted in their tolerization, unless
the triple mAb therapy was instigated. Our results empha-
size the role of combinational immunotherapy approaches
including ISmAbs to impact on agressive and highly
T cell-tolerizing hepatocellular carcinomas.
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